Seawolf Debuts With Combined Seed and Series A Capital

Company Seawolf Event Type Seed and Series A financing ($100 million combined) Modality Redosable LNP-DNA delivery Asset TRIDENT platform; preclinical metabolic lead Target Nuclear-access DNA expression Disease Area Bleeding disorders; metabolic disease Summary Seawolf emerged from stealth reporting $100 million raised across a seed round…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *